智通财经APP讯，中国中药(00570)发布截至2024年12月31日止全年业绩，集团营业额人民币165.1亿元，同比减少8.9%;净利润2077.1万元，同比减少98.5%;每股基本盈利1.07分;拟派末期股息每股0.35港仙及特别股息每股8.3港仙。
尽管阶段性盈利水平承压，但集团核心业态产销规模仍维持稳定，市场占有率持续巩固。基于对中药行业长期发展趋势的深刻洞察以及对企业基本面的充分信心，董事会与管理层对集团跨越短期业绩波动持有乐观态度。
报告期内，集团积极推动企业转型升级和创新发展，中药工业保持规模优势，重点科技项目卓有成效，改革深化工作稳步推进，各类风险有效防控，数字化转型有序开展，各业态经营亦取得阶段性进展：中药材基地建设稳步推进，中药饮片深化区域布局带动上量，中药配方颗粒市场份额稳居领先地位，中成药业态规模持续增长，中医药大健康业务稳步探索增量空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.